Enliven Therapeutics, Inc. (ELVN) — SEC Filings
Enliven Therapeutics, Inc. (ELVN) — 36 SEC filings. Latest: 8-K (Dec 11, 2025). Includes 9 8-K, 7 SC 13G/A, 6 SC 13D/A.
View Enliven Therapeutics, Inc. on SEC EDGAR
Overview
Enliven Therapeutics, Inc. (ELVN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 11, 2025: Enliven Therapeutics, Inc. announced on December 9, 2025, changes in its board and executive team, including the departure of a director and the appointment of new officers. The company also disclosed compensatory arrangements for certain officers and provided a Regulation FD disclosure. This filing
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 33 neutral, 1 mixed. The dominant filing sentiment for Enliven Therapeutics, Inc. is neutral.
Filing Type Overview
Enliven Therapeutics, Inc. (ELVN) has filed 9 8-K, 2 8-K/A, 5 10-Q, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 3 SC 13G, 6 SC 13D/A with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of ELVN's 25 recent filings, 1 were flagged as high-risk, 13 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$20.148M |
| EPS | N/A |
| Debt-to-Equity | 0.0 |
| Cash Position | $101.732M |
| Operating Margin | N/A |
| Total Assets | $597.433M |
| Total Debt | $0 |
Key Executives
- Paul A. Stone
- Samuel Kintz
- Andrew J. Schwab
- Kush Parmar
- Helen Collins MD
- Abigail P. Johnson
Industry Context
Enliven Therapeutics operates in the highly competitive and innovation-driven clinical-stage biopharmaceutical sector. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Companies like Enliven focus on unmet medical needs, often employing precision medicine approaches to target specific patient populations, such as in oncology.
Top Tags
amendment (7) · corporate-governance (4) · sec-filing (4) · 10-Q (4) · 8-K (3) · pharmaceuticals (3) · financials (3) · ownership-change (3) · Enliven Therapeutics (3) · institutional-ownership (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss for Q3 2025 | $20.148M | Decreased from $23.156 million in Q3 2024 |
| Net loss for nine months ended Sept 30, 2025 | $74.027M | Increased from $65.844 million in the same period of 2024 |
| Net proceeds from Public Offering | $216.169M | Significantly boosted cash and stockholders' equity in Q2 2025 |
| Total stockholders' equity as of Sept 30, 2025 | $476.122M | Increased from $309.845 million at December 31, 2024 |
| Cash and cash equivalents as of Sept 30, 2025 | $101.732M | Decreased from $124.117 million at December 31, 2024 |
| Marketable securities as of Sept 30, 2025 | $375.833M | Increased from $189.323 million at December 31, 2024 |
| Research and development expenses for Q3 2025 | $18.225M | Decreased from $21.258 million in Q3 2024 |
| Research and development expenses for nine months ended Sept 30, 2025 | $64.611M | Increased from $60.054 million in the same period of 2024 |
| Shares of common stock outstanding as of Oct 31, 2025 | 59,347,317 | Reflects dilution from recent offerings |
| SEC File Number | 001-39247 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 81-1523849 | Company's tax identification number. |
| Reporting Period | Q1 2025 | Financials for the first quarter of 2025 are detailed. |
| Fiscal Year End | 1231 | Indicates the end of the company's annual financial reporting cycle. |
| Filing Date | 20250428 | Date the DEF 14A was filed with the SEC. |
| Meeting Date | 20250624 | Date of the shareholder meeting for which the proxy statement is issued. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant stake in Enliven Therapeutics, Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
Frequently Asked Questions
What are the latest SEC filings for Enliven Therapeutics, Inc. (ELVN)?
Enliven Therapeutics, Inc. has 36 recent SEC filings from Feb 2024 to Dec 2025, including 9 8-K, 7 SC 13G/A, 6 SC 13D/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ELVN filings?
Across 36 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 33 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Enliven Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Enliven Therapeutics, Inc. (ELVN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Enliven Therapeutics, Inc.?
Key financial highlights from Enliven Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ELVN?
The investment thesis for ELVN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Enliven Therapeutics, Inc.?
Key executives identified across Enliven Therapeutics, Inc.'s filings include Paul A. Stone, Samuel Kintz, Andrew J. Schwab, Kush Parmar, Helen Collins MD and 1 others.
What are the main risk factors for Enliven Therapeutics, Inc. stock?
Of ELVN's 25 assessed filings, 1 were flagged high-risk, 13 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Enliven Therapeutics, Inc.?
Recent forward-looking statements from Enliven Therapeutics, Inc. include guidance on {"claim":"FMR LLC will maintain a significant stake in Enliven Therapeutics, Inc. for the foreseeable future.","entity":.